Literature DB >> 20630539

Sputum induction in routine clinical care of children with cystic fibrosis.

Suhail Al-Saleh1, Sharon D Dell, Hartmut Grasemann, Yvonne C W Yau, Valerie Waters, Sean Martin, Felix Ratjen.   

Abstract

OBJECTIVE: To determine the microbiological yield of induced sputum (IS) samples compared with conventional airway samples, spontaneously expectorated sputum and throat swabs, in children with cystic fibrosis (CF) attending an outpatient clinic. STUDY
DESIGN: Ninety-five children with CF (75 able to spontaneously expectorate sputum) were included in this prospective cross-sectional comparative study. After obtaining expectorated sputum or throat swabs samples, IS was obtained by performing the sputum induction procedure using an eFlow device (PARI, Starnberg, Germany). CF bacterial culture results were compared between the two procedures.
RESULTS: Differences in culture results between samples were observed in 25 of 94 (27%) patients. IS had a significantly higher yield for CF pathogens, with 80% of the differences being due to detection of additional organisms in IS samples. Overall, SI was well tolerated, but 12 of 95 cases had a >20% postinduction decline in forced expiratory volume in 1 second. The whole SI procedure took 30 to 85 minutes of clinic time, and its estimated additional cost was $150 (US)/patient.
CONCLUSIONS: Induced sputum has a higher microbiological yield compared with the conventional samples in children with CF, even in patients capable of expectorating sputum spontaneously. Although sputum induction is safe and tolerable, it is time-consuming and expensive in routine clinical settings.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20630539     DOI: 10.1016/j.jpeds.2010.06.001

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  Procedures for collection of induced sputum specimens from children.

Authors:  Lindsay R Grant; Laura L Hammitt; David R Murdoch; Katherine L O'Brien; J Anthony Scott
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

2.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

3.  Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.

Authors:  Jennifer Ruddy; Julia Emerson; Richard Moss; Alan Genatossio; Sharon McNamara; Jane L Burns; Gail Anderson; Margaret Rosenfeld
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-05-23       Impact factor: 2.849

4.  Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis.

Authors:  Paul C Blainey; Carlos E Milla; David N Cornfield; Stephen R Quake
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

5.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

Review 6.  Specimen collection for the diagnosis of pediatric pneumonia.

Authors:  Laura L Hammitt; David R Murdoch; J Anthony G Scott; Amanda Driscoll; Ruth A Karron; Orin S Levine; Katherine L O'Brien
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

Review 7.  Novel outcome measures for clinical trials in cystic fibrosis.

Authors:  Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz
Journal:  Pediatr Pulmonol       Date:  2014-12-30

8.  Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Authors:  Francis J Gilchrist; John Belcher; Andrew M Jones; David Smith; Alan R Smyth; Kevin W Southern; Patrik Španěl; A Kevin Webb; Warren Lenney
Journal:  ERJ Open Res       Date:  2015-11-16

9.  L-ornithine derived polyamines in cystic fibrosis airways.

Authors:  Hartmut Grasemann; Darakhshanda Shehnaz; Masahiro Enomoto; Michael Leadley; Jaques Belik; Felix Ratjen
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.